The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar-Reference-Cited by-同舟云学术

The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar

Published:2016-08-02 Issue:1 Volume:6 Page:14-16
ISSN:2157-6564
Container-title:Stem Cells Translational Medicine
language:en
Short-container-title:

Author:

Knoepfler Paul S.¹²³

Affiliation:

1. a Department of Cell Biology and Human Anatomy, University of California Davis School of Medicine, Davis, California, USA

2. b Genome Center, University of California Davis School of Medicine, Davis, California, USA

3. c Institute of Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA

Abstract

Abstract The growing direct-to-consumer, stem cell clinic industry in the U.S. uses a number of strategies for patient recruitment, including self-styled educational seminars, which may reach thousands of members of the public annually. Here I report on a first-hand experience at such a seminar that I recently attended. Numerous specific medical claims were made at the seminar: no potential for rejection; no side effects, including no pain; proven efficacy for a variety of conditions, including in particular arthritis and pain; and U.S. Food and Drug Administration approval. I discuss the potential impact of these kinds of seminars on the public and on the stem cell field. Stem Cells Translational Medicine 2017;6:14–16

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

Link

https://academic.oup.com/stcltm/article-pdf/6/1/14/41893413/stcltm_6_1_14.pdf

Reference8 articles.

1. Regulation: Sell help not hope;Bianco;Nature.,2014

2. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions;Turner;Regen Med.,2015

3. Medicine on the fringe: Stem cell-based interventions in advance of evidence;Regenberg;STEM CELLS.,2009

4. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: Is it getting better?;Ogbogu;Regen Med.,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies;Regenerative Medicine;2023-10-23

2. Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies;Regenerative Medicine;2023-10

3. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products;Cytotherapy;2023-09

4. Online seminars as an information source for direct-to-consumer stem cell therapy;Regenerative Medicine;2022-02

5. The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation;Journal of Primary Care & Community Health;2022-01